EcoR1 Capital, LLC

September 30, 2026

Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.

September 25, 2026

Evercore initiates coverage on TRAX with Outperform rating. Evercore ISI Group began coverage of First Tracks Biotherapeutics with an Outperform rating and a $65 price target. This adds to a bullish analyst narrative, as the average target from 11 analysts stands at $71.82. The stock is currently trading near its 52-week low, with recent volume spikes indicating heightened market attention.

October 1, 2026

AKTS launches second Phase 1b trial for AKY-2519. Aktis Oncology announced the start of a second Phase 1b clinical trial for its AKY-2519 candidate. The trial follows earlier testing and moves the drug further along the development pathway. This progress adds to the company's pipeline activity while the stock remains in a low RSI region, indicating recent price weakness.

October 13, 2026

ZYME News Highlights Potential Undervaluation and Raised Price Target. Recent coverage notes that Zymeworks may be about 39% undervalued based on its 2026 revenue guidance and the recent appointment of a chief investment officer. Truist Securities also kept its rating and lifted its price target to $34, reflecting continued confidence in the company's outlook.

September 25, 2026

Prothena included in Alzheimer's Day stock watchlist. Prothena was featured in a Yahoo Finance article listing four Alzheimer's drug stocks to watch on World Alzheimer's Day. This inclusion highlights the company's relevance in the neurodegenerative disease sector. The stock is currently trading near its 52-week low, with technical indicators showing a rejection at support levels.

October 13, 2026

AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.

October 16, 2026

Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.

October 15, 2026

Corvus Pharma Q2 2026 Earnings Call Transcript Released. Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.